| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Tanaka | |
| Oku | |||
| Araki | |||
| Ebihara | |||
| Miki Honda | |||
| Asai | |||
| P2860 | cites work | Drug delivery systems: entering the mainstream | Q29618136 |
| Ocular drug delivery | Q30475605 | ||
| Anti-neovascular therapy using novel peptides homing to angiogenic vessels | Q30833114 | ||
| Effect of particle size of polymeric nanospheres on intravitreal kinetics | Q30976557 | ||
| NEGATIVE STAINING OF PHOSPHOLIPIDS AND THEIR STRUCTURAL MODIFICATION BY SURFACE-ACTIVE AGENTS AS OBSERVED IN THE ELECTRON MICROSCOPE. | Q30994466 | ||
| Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. | Q33207041 | ||
| Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy | Q33419661 | ||
| Intravitreal pharmacokinetics of plain and liposome-entrapped fluconazole in rabbit eyes. | Q51369781 | ||
| Selective release of non-electrolytes from liposomes upon perturbation of bilayers by temperature change or polyene antibiotics. | Q52506182 | ||
| Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes | Q56386325 | ||
| Ocular Neovascularization | Q60060646 | ||
| Liposome suppression of proliferative vitreoretinopathy. Rabbit model using antimetabolite encapsulated liposomes | Q68009906 | ||
| Liposome-bound cyclosporine: retinal toxicity after intravitreal injection | Q68039224 | ||
| Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model | Q68836468 | ||
| Toxicity and clearance of a combination of liposome-encapsulated ganciclovir and trifluridine | Q69257158 | ||
| Intravitreal liposome-encapsulated gentamicin in a rabbit model. Prolonged therapeutic levels | Q69548281 | ||
| Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits | Q70110894 | ||
| Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Use of the experimental drug 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine | Q70156317 | ||
| Pharmacokinetics of intravitreally injected liposome-encapsulated tobramycin in normal rabbits | Q70247392 | ||
| Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis | Q70804644 | ||
| The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975 | Q71417583 | ||
| Intravitreal pharmacokinetics of liposome-encapsulated amikacin in a rabbit model | Q72587651 | ||
| Suture loop to aid in ganciclovir implant removal | Q73017245 | ||
| Retinal toxicity of liposome-incorporated and free ofloxacin after intravitreal injection in rabbit eyes | Q73149344 | ||
| Anticancer therapy using glucuronate modified long-circulating liposomes | Q73850591 | ||
| Ocular novel drug delivery: impacts of membranes and barriers | Q81309134 | ||
| Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. | Q33837747 | ||
| Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416. | Q33845753 | ||
| Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. | Q34062411 | ||
| Microemulsions as ocular drug delivery systems: recent developments and future challenges | Q34572807 | ||
| Nanotech approaches to drug delivery and imaging | Q35609123 | ||
| Drug delivery systems for vitreoretinal diseases | Q35792000 | ||
| Ligand-targeted liposomes for cancer treatment | Q36320811 | ||
| Expression of vascular endothelial growth factor in experimental choroidal neovascularization | Q36851954 | ||
| Vascular endothelial growth factor expression in choroidal neovascularization in rats | Q36864325 | ||
| Dendrimers as drug carriers: applications in different routes of drug administration | Q36920235 | ||
| Microemulsions as potential drug delivery systems: a review | Q37134369 | ||
| Recent perspectives in ocular drug delivery | Q37256549 | ||
| Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS | Q37308378 | ||
| Intravitreal injection of therapeutic agents | Q37544116 | ||
| Recent advances in intraocular drug delivery systems | Q37818398 | ||
| Drug delivery to the posterior segment of the eye. | Q37822010 | ||
| Nanomaterials for ocular drug delivery | Q38003088 | ||
| Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis | Q38495949 | ||
| Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres | Q38564886 | ||
| In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release | Q38569871 | ||
| Liposomes in immunology: multilamellar phosphatidylcholine liposomes as a simple, biodegradable and harmless adjuvant without any immunogenic activity of its own. | Q38576448 | ||
| Transport processes across the rabbit corneal epithelium: a review | Q39824554 | ||
| Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. | Q39972163 | ||
| Intravitreal ganciclovir in the treatment of AIDS-associated cytomegalovirus retinitis | Q42200749 | ||
| Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. | Q43086468 | ||
| Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes | Q43158628 | ||
| Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group | Q43410915 | ||
| Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes | Q43716420 | ||
| Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. | Q43843378 | ||
| Liposomally-entrapped ganciclovir for the treatment of cytomegalovirus retinitis in AIDS patients. Eperimental toxicity and pharmacokinetics, and clinical trial | Q44062718 | ||
| Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor | Q44196277 | ||
| Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model | Q44417304 | ||
| Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. | Q44526900 | ||
| Microspheres of biodegradable polymers as a drug-delivery system in the vitreous | Q44856271 | ||
| In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits | Q44935883 | ||
| New vehicle based on a microemulsion for topical ocular administration of dexamethasone. | Q45170985 | ||
| Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. | Q46017257 | ||
| Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients | Q46064973 | ||
| Retinal toxicity of the antimetabolite 5-fluorouridine 5'-monophosphate administered intravitreally using multivesicular liposomes. | Q46130863 | ||
| Ocular toxicity of intravitreally injected liposomal amphotericin B in rhesus monkeys. | Q49197627 | ||
| Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes. | Q50070864 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanotechnology | Q11468 |
| nanomedicine | Q261659 | ||
| liposome | Q410454 | ||
| eye disease | Q3041498 | ||
| manufactured product | Q3406743 | ||
| pharmaceutical preparation | Q66089252 | ||
| P304 | page(s) | 495-503 | |
| P577 | publication date | 2013-01-01 | |
| 2013-02-14 | |||
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Liposomes and nanotechnology in drug development: focus on ocular targets | |
| P478 | volume | 8 |
| Q38406190 | Advances in lipid-based drug delivery: enhancing efficiency for hydrophobic drugs |
| Q38217270 | Colloidal drug delivery system: amplify the ocular delivery |
| Q38902191 | Current advances in the treatment of neovascular age-related macular degeneration |
| Q64064786 | Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection |
| Q47444145 | Diclofenac sodium ion exchange resin complex loaded melt cast films for sustained release ocular delivery |
| Q42360534 | Dorzolamide Loaded Niosomal Vesicles: Comparison of Passive and Remote Loading Methods |
| Q38161953 | Drug delivery techniques for treating age-related macular degeneration |
| Q37225620 | Efficacy and safety of dendrimer nanoparticles with coexpression of tumor necrosis factor-α and herpes simplex virus thymidine kinase in gene radiotherapy of the human uveal melanoma OCM-1 cell line |
| Q40992924 | High Throughput Screening of Valganciclovir in Acidic Microenvironments of Polyester Thin Films |
| Q53451278 | How can nanoparticles be used to overcome the challenges of glaucoma treatment? |
| Q26823895 | Lipid Nanoparticles for Ocular Gene Delivery |
| Q38837906 | Lipid-based drug delivery systems in the treatment of wet age-related macular degeneration. |
| Q41985198 | Mechanism of the anticataract effect of liposomal MgT in galactose-fed rats |
| Q38831205 | Nanocrystal for ocular drug delivery: hope or hype |
| Q38193067 | Nanodrugs: pharmacokinetics and safety |
| Q35224472 | Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization |
| Q54222185 | Nanoparticles as Delivery Vehicles for the Treatment of Retinal Degenerative Diseases. |
| Q39049314 | Nanoparticles for the delivery of therapeutic antibodies: Dogma or promising strategy? |
| Q26746982 | Novel Strategies for the Improvement of Stem Cells' Transplantation in Degenerative Retinal Diseases |
| Q34571360 | Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling |
| Q36628814 | Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes |
| Q53655341 | Preparation and ocular pharmacokinetics of hyaluronan acid-modified mucoadhesive liposomes. |
| Q38196446 | Topical delivery of ocular therapeutics: carrier systems and physical methods. |
| Q89455321 | Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases |
| Q50129671 | [Nanoparticles as drug delivery systems in ophthalmology]. |
Search more.